H.C. Wainwright lowered the firm’s price target on Oculis (OCS) to $29 from $30 and keeps a Buy rating on the shares following the Q4 report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions
- Oculis Holding AG Reports 2024 Financial Results
- Oculis Holding’s Promising Ophthalmology Portfolio and Financial Stability Lead to Buy Rating
- Oculis Holding AG Reports 2024 Financial Results and Clinical Progress
- Oculis 5M share Secondary priced at $20,00